Employees: 3,415
Size Yabao Pharmaceutical (600351.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $678M, the 2961st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.54 on 18 Nov 2026.
Performance Over six months the shares fell 0.1%, against -14.5% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue fell 3.5% over the last twelve months (peer median +7.1%); the operating margin is 15.6% (peer median 9.5%).
Valuation It trades at 1.6× enterprise value to sales against a peer median of 2.5× (6th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 12.1 points above its cost of capital (6.8% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.19B | CN¥2.22B | CN¥2.67B | CN¥2.89B | CN¥2.70B |
| Revenue growth | — | -17% | -8% | +7% | — |
| Gross profit | CN¥1.25B | CN¥1.11B | CN¥1.31B | CN¥1.60B | CN¥1.43B |
| EBITDA | n/a | CN¥453M | CN¥424M | CN¥449M | CN¥335M |
| Net income | CN¥362M | CN¥320M | CN¥243M | CN¥200M | CN¥105M |
| Free cash flow | CN¥613M | CN¥529M | CN¥440M | CN¥398M | CN¥403M |
| Capital expenditure | CN¥33.9M | CN¥48.9M | CN¥34.7M | CN¥99.9M | CN¥62.2M |
| Total debt | CN¥3.80M | CN¥38.5M | CN¥95.7M | CN¥268M | CN¥450M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600351.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.3% | -2.8% | 10th lowest of 21 |
| 6-month return | -0.1% | -14.5% | 7th highest of 21 |
| Distance from 52-week high | -12.2% | -35.3% | 3rd highest of 21 |
| Revenue growth (TTM) | -3.5% | +7.1% | 5th lowest of 18 |
| Operating margin | 15.6% | 9.5% | 5th highest of 18 |
| EV / Sales | 1.6× | 2.5× | 6th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -8.3% | 25.2% | least demanding of 10 |
| Growth delivered (Del g) | -2.8% | +7.9% | lowest of 10 |
| Hurdle (Req g minus delivered) | -5.5 pp | +1.2 pp | 2nd least demanding of 10 |
| ROIC minus cost of capital | +12.1 pp | -0.3 pp | highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | 1.6× | -8.3% | -2.8% |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 1.7× | n/a | n/a |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 0.9× | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 6.7× | 31.9% | +19.8% |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 2.5× | n/a | n/a |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 0.5× | -1.6% | -1.8% |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | 2.5× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | 0.6× | 4.0% | +5.3% |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | 2.4× | 25.2% | +10.3% |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 3.4× | 27.1% | +31.4% |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 0.8× | n/a | n/a |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | 0.3× | n/a | n/a |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | 10.6× | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 3.0× | 9.1% | +7.9% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 2.6× | -4.8% | +6.4% |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | 12.8× | 36.3% | +16.2% |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 3.9× | n/a | n/a |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | 16.1× | 42.7% | -0.9% |